Health Economics Studies and Research

As part of the Biostatistics and Epidemiology Office at Gustave Roussy and the Oncostat research team “Methodology and Clinical Epidemiology in Molecular Oncology,” our missions are to:

• Conduct economic evaluations of health strategies. We are involved in projects under the DGOS’s hospital research programs (PHRC, PRME, PREPS), RHU/IHU initiatives, and European projects.
• Design and conduct health economics research using data from clinical trials, surveys, prospective cohorts, or medical-administrative data.
• Participate in teaching (Master’s in Market Access and Health Economic Evaluation, Master’s in Health Economics) and in scientific leadership in health economics (College of Health Economists, ESMO Public Policy Committee).

Resource Use in Oncology

To quantify the resources allocated by the public sector to the management of certain cancers, we conduct cost studies using data from the National Health Data System (cost of acute myeloid leukemia as part of the SIRIC Epicure project) and cohort data such as COBLAnCE, a prospective cohort of patients with bladder cancer.

Efficiency and Budgetary Impact of Cancer Interventions

We apply economic evaluation methods to various areas of oncology: prevention and screening initiatives, diagnostic strategies, treatments, supportive care, and models of care organization. We also conduct research on these methodologies.

Costs and Access to Innovations in Oncology

Using surveys and medical-administrative databases (PMSI and SNDS), we evaluate national programs such as the France Genomic Medicine 2025 Plan, the impact of pricing mechanisms (e.g., RIHN), and access to innovations in molecular biology and novel treatments.

Publications: Studies and Research in Health Economics 2024–25

• PFMG2025 contributors. PFMG2025—Integrating Genomic Medicine into the National Healthcare System in France. Lancet Reg Health Eur 2025
• Fraslin AM, Stockholm T, Filleron T, Bertaut A, Blanc-Lapierre A, Marghadi J, Aupérin A, Bonastre J.
  A microsimulation model based on healthcare pathways to estimate the impact of COVID-19 pandemic-induced delays on breast cancer mortality. Journal of Clinical Epidemiology 2025
• Fraslin AM, Benhamou S, Lebret T, Radvanyi F, Allory Y, Karimi M, Bonastre J. Incidence of Bladder Cancer, Healthcare Pathways, and Economic Burden: A Real-World Observational Study From the French National Healthcare System Database. Clinical Genitourinary Cancer 2025
• Negrier S, Bonastre J, Colrat F, Teitsson S, Knight C, Ni L, Chevalier J, Branchoux S, Rouprêt M.
  Cost-effectiveness of nivolumab compared with surveillance for adjuvant treatment of muscle-invasive urothelial carcinoma at high risk of recurrence in France. World Journal of Urology 2025
• Fraslin A, Colrat F, Karimi M, Bonastre J, Groussard K, Teitsson S, Prudent A, Branchoux S, Radvanyi F, Benhamou S, Allory Y, Lebret T. Characteristics, management, and survival outcomes in patients with muscle-invasive bladder cancer at high risk of recurrence in France: a subgroup analysis from the Coblance cohort. BMC Urology 2025
• Fraslin AM, Aupérin A, Even C, Fayette J, Saada-Bouzid E, Lafond C, Geoffrois L; TPExtreme-ECO Group; Bourhis J, Guigay J, Bonastre J. Cost-Utility Analysis Alongside the GORTEC 2014-01 TPExtreme Trial: TPEx Versus EXTREME as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Value in Health 2025
• Leleu H, Berkovitch Q, Bonastre J, Caramella C, Giroux-Leprieur É, Lefèvre L, Lavaud P, Todea A, Wislez M, Hofman P. Efficacy and cost-effectiveness of lung cancer screening in France using low-dose computed tomography. European Journal of Cancer Prevention 2025
• Lefèvre G, Borget I, Lefèvre C, Maherzi C, Nucit A, Hennaoui M, Schmidt A, Lennon H, Grenier B, Daydé F, Mahlaoui N. Healthcare resource utilization and costs in immunodeficient patients receiving subcutaneous Ig: Real-world evidence from France. PLoS ONE 2025
• Wislez M, Giannopoulou A, Borget I, Lindsay C, Rothschild SI, Vincent B, Milce J, Sultan I, Stollenwerk B, Pless M. Clinical characteristics, healthcare resource use, and survival outcomes among patients with advanced NSCLC tested for KRAS mutations in France, the United Kingdom, and Switzerland. Journal of Medical Economics 2025
• Borget I, Benchaib M, Poignant P, Rey L, Harty G, Chaudhari V, D’hooghe T, Schwarze JE, Cedrin Durnerin I, Roeder C, Grynberg M. A Cost-Effectiveness Analysis of Gonadotropins Used for Ovarian Stimulation during Assisted Reproductive Technology Based on Data from the French Nationwide Claims Database (SNDS). Gynecologic and Obstetric Investigation 2025
• Body C, Chassagnol F, Berdaï D, Bergmann JF, Borget I, Doré C, Durr A, Falissard B, Hudry J, Kowalski B, Maugendre P, Schlumberger N, Wilmet E, Le Jeunne C. How to Differentiate Between Drugs with Clinical Added Value (CAV): What Are the Implications, and What Is the Access Pathway? *Thérapie* 2025
• Costa N, Gombault E, Marcélo C, Pagès A, Molinier L, de Souto Barreto P, Rolland Y. Association between limitations in intrinsic capacities and annual healthcare costs among nursing home residents. BMC Geriatrics 2025
• Garcia-Foncillas J, Bayle A, Arnold D, Avouac B, Awada A, de la Cruz-Merino L, Helland Å, Lassen U, Laurent-Puig P, Normanno N, Rohrberg K, Taieb J, Stenzinger A. Overcoming barriers to advanced biomolecular technologies that inform the treatment of solid tumors: a roadmap to access. Future Oncology
  2025
• Lueza B, Aupérin A, Rigaud C, Gross TG, Pillon M, Delgado RF, Uyttebroeck A, Amos Burke GA, Zsíros J, Csóka M, Simonin M, Patte C, Minard-Colin V, Bonastre J. Cost-effectiveness analysis alongside the Inter-B-NHL Ritux 2010 trial: rituximab in children and adolescents with B-cell non-Hodgkin lymphoma. Eur J Health Econ. 2024
• Rousseau A, Michiels S, Simon-Tillaux N, Lolivier A, Bonastre J, Planchard D, Barlesi F, Remon J, Lavaud P, Aldea M, Frelaut M, Le Pechoux C, Botticella A, Levy A, Gazzah A, Foulon S, Besse B. Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort study. Lancet Reg Health Eur 2024
• Mosele MF, Westphalen CB, Stenzinger A, Barlesi F, Bayle A, Bièche I, Bonastre J, Castro E, Dienstmann R, Krämer A, Czarnecka AM, Meric-Bernstam F, Michiels S, Miller R, Normanno N, Reis-Filho J, Remon J, Robson M, Rouleau E, Scarpa A, Serrano C, Mateo J, André F. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2024
• Bayle A, Chaltiel D, Latino N, Rouleau E, Peters S, Galotti M, Bricalli G, Besse B, Giuliani R, Bonastre J. Reply to the Letter to the Editor regarding “Overcoming Barriers in Biomarker Testing” by J. García-Foncillas et al. Ann Oncol. 2024
• Bayle A, Marino P, Baffert S, Margier J, Bonastre J. Cost of high-throughput sequencing (NGS) technologies: Literature review and insights. Bull Cancer. 2024
• Farah L, Borget I, Martelli N, Vallee A. Suitability of the Current Health Technology Assessment of Innovative Artificial Intelligence-Based Medical Devices: Scoping Literature Review. J Med Internet Res. 2024
• Martin T, Rioufol C, Favier B, Martelli N, Madelaine I, Chouaid C, Borget I. Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and Costs. BioDrugs. 2024
• Borget I, Benchaib M, Poignant P, Rey L, Harty G, Chaudhari V, D’hooghe T, Schwarze JE, Cedrin Durnerin I, Roeder C, Grynberg M. A Cost-Effectiveness Analysis of Gonadotropins Used for Ovarian Stimulation during Assisted Reproductive Technology Based on Data from the French Nationwide Claims Database (SNDS). Gynecol Obstet Invest. 2024
• Grumberg V, Cotté FE, Giroux-Leprieur E, Gaudin AF, Lebbé C, Borget I. Clinical benefit of anti-PD-(L)1 immunotherapies in advanced cancer in France: a population-based estimate from 2014 to 2021. ESMO Open. 2024
• Cartron G, Thieblemont C, Borget I, Rioufol C, Berthet M, Portal C, Baujat C, Alaoui E, Baffert S, Lacroix D, Bories P, Yakoub-Agha I, Houot R. Real-world evaluation of the care pathway for patients eligible for treatment with axicabtagene ciloleucel: the IMPA-CT multicenter cohort. Bull Cancer 2024
• Horgan D, Pesapane F, Van der Buckle M, de Maria R, Dube F, Singh J, Ługowska I, Bayle A, Hofman P, Malapelle U, Hills T, Capoluongo ED, Subbiah V. From theory to practice: Implementing next-generation sequencing and public health genomics in healthcare systems. Crit Rev Oncol Hematol 2024

Publications: Studies and Research in Health Economics 2014–23

Team Members

• Julia BONASTRE, ERES Team Leader, Economist, PhD in Economics
• Isabelle BORGET, Pharmacist / PhD in Public Health (Economics), Associate Professor and Public Health Specialist
• Arnaud PAGES, Pharmacist / PhD in Health Economics and Epidemiology
• Stéphanie FOULON, Public Health Physician, PhD in Public Health (Epidemiology)
• Arnaud BAYLE, Oncologist, PhD in Public Health (Economics)
• Aldéric FRASLIN, Statistician/Economist, PhD in Public Health (Economics)
• Farah ERDOGAN, PhD Candidate in Public Health (Economics)
• Lou-Anne PERETTI, PhD Candidate in Public Health (Economics)
• Océane VRAY, Master’s student (M2) in Market Access and Health Economics Evaluation (work-study program)